Polaris Partners

Polaris Partners, established in 1996 and headquartered in Boston, Massachusetts, is a venture capital firm focusing on healthcare, life sciences, and biotechnology sectors. The firm invests across various stages, from early-stage companies to growth equity, partnering with repeat entrepreneurs and innovators. Polaris' healthcare portfolio spans digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics, while its life sciences and biotechnology investments center around molecules, platforms, therapeutics, and genomics. With offices in Boston and San Francisco, Polaris has a 20-year history of supporting companies that improve people's lives and work.

Marissa Bertorelli

Principal

Alexandra Cantley

Partner

Darren Carroll

Managing Partner

Brian Chee

Managing Partner

Isaac Ciechanover

Partner

Jon Flint

Founding Partner

Harold Friedman

CFO

John Gannon

CFO and Partner

Nil Gural

Senior Associate

Rahul Kakkar

Entrepreneur Partner

Pat Kinsel

Partner

Dan Lombard

Partner

Eileen McGuire

Partner

Ellie McGuire

Partner

Pat Mulach

Associate

Kim Png Ph.D

Principal

Amy Schulman

Managing Partner

Gary Swart

Partner

Jim Weinstein

Entrepreneur Partner

Past deals in Nanotechnology

Glympse Bio

Series B in 2020
Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

Glympse Bio

Series A in 2018
Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

Cerulean Pharma

Private Equity Round in 2012
Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Cerulean Pharma

Series D in 2011
Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Cerulean Pharma

Series C in 2010
Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

BIND Therapeutics

Series C in 2010
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

Cerulean Pharma

Series B in 2009
Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Cerulean Pharma

Series B in 2008
Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

BIND Therapeutics

Series B in 2007
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

Cerulean Pharma

Series A in 2007
Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

BIND Therapeutics

Series A in 2007
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

Cerulean Pharma

Venture Round in 2006
Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics aimed at treating oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on nanoparticle-drug conjugates that target tumors, reduce toxicity, and facilitate therapeutic combinations. Among its notable products is Ovaprene, a contraceptive designed to offer hormone-free protection for multiple weeks. Cerulean has established a distinguished management team and advisory board, drawing from extensive experience in product development and scientific innovation from renowned institutions and companies in the biopharmaceutical sector.

Nanosys

Series C in 2005
Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.

Nanosys

Series B in 2003
Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.

Nanosys

Series A in 2002
Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.

Nanosys

Seed Round in 2001
Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.